首页 / 院系成果 / 成果详情页

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial  期刊论文  

  • 编号：
    E36437A560D401C8ED5A9B38D23F9649
  • 作者：
    Sun, Yang[1] Yang, Hongying[2] Wang, Jing[3] Lou, Hanmei[4] Li, Dan[5] Wang, Ke[6] Zhang, Hui[7] Wu, Tao[8] Li, Yuzhi[9] Wang, Chunyan[10] Li, Guiling[11] Wang, Yifeng[12] Li, Dapeng[13] Tang, Ying[14] Pan, Mei[15] Cai, Hongyi[16] Wang, Weihu[17] Yang, Bing[18] Qian, Hua[19] Tian, Qiuhong[20] Yao, Desheng[21] Cheng, Ying[22] Wei, Bing[23] Li, Xiumin[24] Wang, Tao[25] Hao, Min[26] Wang, Xiaohong[27] Wang, Tiejun[28] Liu, Chang[29] Zhu, Hong[30] Zhu, Lijing[31] Liu, Xianling[32] Li, Yunxia[33] Chen, Lihong[34] Li, Qingshan[35] Yan, Xiaojian[36] Wang, Fei[37] Cai, Hongbing[38] Zhang, Yunyan[39] Liang, Zhiqing[40] Liu, Funan[41] Huang, Yi[42] Xia, Bairong[43] Qu, Pengpeng[44] Zhu, Genhai[45] Chen, Youguo[46] Song, Kun[47] Sun, Meili[48] Chen, Zhengzheng[49] Zhou, Qiang[50] Hu, Lina[51] Abulizi, Guzhalinuer[52] Guo, Hongyan[53] Liao, Sihai[54] Ye, Yijing[55] Yan, Ping[56] Tang, Qiu[57] Sun, Guoping[58] Liu, Ting[59] Lu, Dongmei[59] Hu, Mingxiu[59] Wang, Zhongmin M.[59] Li, Baiyong[59] Xia, Michelle[59] Wu, Xiaohua[60]
  • 语种：
    英文
  • 期刊：
    NATURE COMMUNICATIONS ISSN：2041-1723 2026 年 17 卷 1 期 ; MAR 14
  • 收录：
     
  • 摘要：

    The phase 3 COMPASSION-16 trial demonstrates significant progression-free survival (PFS) and overall survival (OS) benefits with cadonilimab plus standard therapy in patients with persistent, recurrent, or metastatic cervical cancer. This analysis aims to assess efficacy outcomes in patient subgroups of COMPASSION-16. The dual primary endpoints of COMPASSION-16 are PFS, assessed by the blinded independent central review (BICR) according to RECIST version 1.1, and OS. The secondary endpoint is objective response rate. In this subgroup analysis, the PFS, OS and objective response rate are evaluated in subgroups including bevacizumab use, prior concurrent chemoradiotherapy, PD-L1 combined positive score (CPS), metastatic disease at baseline, platinum use, and age. With median follow-up of 25.6 months, hazard ratios (HRs) for PFS favour cadonilimab group in all subgroups. Moreover, the addition of cadonilimab is also associated with prolonged overall survival. This subgroup analysis confirms that improvements in progression-free and overall survival are consistent with the primary results of the COMPASSION-16 study across diverse patient profiles.

  • 推荐引用方式
    GB/T 7714：
    Sun Yang,Yang Hongying,Wang Jing, et al. Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial [J].NATURE COMMUNICATIONS,2026,17(1).
  • APA：
    Sun Yang,Yang Hongying,Wang Jing,Lou Hanmei,&Wu Xiaohua.(2026).Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial .NATURE COMMUNICATIONS,17(1).
  • MLA：
    Sun Yang, et al. "Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial" .NATURE COMMUNICATIONS 17,1(2026).
  • 入库时间：
    5/8/2026 4:11:10 PM
  • 更新时间：
    5/8/2026 4:11:10 PM
浏览次数：7 下载次数：0
分享到：
浏览次数：7
下载次数：0
打印次数：0

网站总浏览量： 次   

Copyright © 山东大学齐鲁医院

技术支持：北京同舟云网络信息技术有限公司

浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部